

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT		Docket Number: 10793/44	00,000
Application Number 10/032,037	Filing Date December 31, 2001	Examiner	Art Unit 1614
Invention Title Y1-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED MOIETIES, ANTIBODIES TO SUCH EPITOPES, AND USES THEREOF		Inventor(s) A. LEVANON et	t al.

Address to:

Commissioner for Patents Washington D.C. 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents & Trademarks, Washington, D.C. 20231.

Date: Angust 2, 2002

Kathryn M. Lumb, Reg. No. 46,885

- 1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
- A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
- 3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: Aug. 2, 2002

By:

Kalhryn M. Lumb (Reg. No. 46,885)

KENYON & KENYON One Broadway New York, N.Y. 10004

(212) 425-7200 (telephone) (212) 425-5288 (facsimile)



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT Application Number 10/032,037 Invention Title Y1-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED MOIETIES, Docket Number: 10793/44 Examiner Art Unit 1614 Inventor(s) A. LEVANON et al.

Address to:

THEREOF

Commissioner for Patents Washington D.C. 20231

ANTIBODIES TO SUCH EPITOPES, AND USES

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents & Trademarks, Washington, D.C. 20231.

Date: Augus

Kathryn M. Lumb, Reg. No. 46,885

- 1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
- A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
- 3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: Aug. 2, 2002

By:

Kathryn M. Lymb (Reg. No. 46,885)

KENYON & KENYON One Broadway New York, N.Y. 10004 (212) 425-7200 (telephone) (212) 425-5288 (facsimile)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449

ATTY. DOCKET NO. **10793/44**

SERIAL NO. 10/032₃037

APPLICANT(S) LEVANON, et al.

FILING DATE
December 31, 2001

GROUP 1614

7007



U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	INVENTORS NAME
	5,223,409	6/29/93	Ladner et al.
	5,403,484	4/4/95	Ladner et al.
	5,427,908	6/25/95	Dower et al.
	5,432,018	7/11/95	Dower et al.
	5,702,954	2/24/98	Hudziak et al.
l	5,763,215	6/9/98	Blumberg et al.
	5,795,776	8/18/98	Fischer
	5,821,337	10/13/98	Carter et al.
	5,843,439	12/1/98	Anderson et al.
	5,945,304	8/31/99	Fischer

FOREIGN PATENT DOCUMENTS

				TRANSLA	ATION
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	YES	NO
	WO 94/26787	11/24/94	PCT		
	WO 00/29004	5/25/00	PCT		
	EP 0 589 877	11/13/96	Europe		



OTHER DOCUMENTS

RECEIVED
AUG 0 8 2002

	Trous
EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Altschul et al. "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Research, 1997, vol. 25, no. 17, pp. 3389-3402
	Bass, et al. "Hormone Phage: An enrichment method for variant proteins with altered binding properties", Proteins: Structure, Function and Genetics, 1990 vol. 8, pp. 309-314
	Caron et al., "Murine and Humanized Constructs of Monoclonal Antibody M195 (Anti-CD33) for the therapy of acute myelogenous leukemia", Cancer Supplement, Feb. 1, 1994, vol. 73, no. 3, pp.1049-1056
	Caron et al., "A Phase 1B trial of humanized monoclonal antibody M195 (Anti-CD33) in myeloid leukemia: specific targeting without immunogenicity"
	Cwirla et al., "Peptides on phage: a vast library of peptides for identifying ligands", Proc. Nat'l. Acad. Sci. USA, August 1990, vol. 87, pp. 6378-6382
	Devlin et al., "Random peptide libraries: a source of specific protein binding molecules", Science, vol 249, pp. 404-406
	Griffiths et al., "Isolation of high affinity human antibodies directly from large synthetic repertoires," EMBO Journal, 1994, vol. 13, no. 14, pp. 3245-3260
	Henkart, "Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules", Immunity, August 1984, vol. 1, pp. 343-346
	Holliger et al., " "Diabodies": small bivalent and bispecific antibody fragments", Proc. Nat'l. Acad. Sci, USA, July 1993, vol. 90, pp. 6444-6448
	Hudson et al., "High avidity scFv multimers; diabodies and triabodies", Journal of Immun. Methods, 1999, vol. 231, pp. 177-189
	Jarvik et al., "Epitope Tagging", Annu. Rev. Genet., 1998, vol. 32, pp. 601-618
	Jurcic et al., ABSTRACT #2528, Blood, 1992 (10 Suppl. Part 1-2)
	Kortt et al., "Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer", Protein Engineering, 1997, vol. 10, no. 4, pp. 423-433
	McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains", Nature, Dec. 6, 1990, vol. 348, pp. 552-554
	McGraw et al., "Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias", Cancer Immunol. Immunotherapy, 1994, vol. 39, pp. 367-374
	Nissim et al., "Antibody fragments from a 'single pot' phage display library as immunochemical reagents", EMBO Journal, 1994, vol. 13, no. 3, pp. 692-698
	Scott et al., "Searching for peptide ligands with an epitope library", Science, July 27, 1990, vol. 249, pp. 386-390
	Sgouros et al. ABSTRACT #979, J. Nucl. Med. Vol. 38 (5 Suppl.)
	Sievers et al., ABSTRACT #2246, Blood, vol. 90 (10 Suppl. 1 Part 1)
	Smith, "Filamentous Fusion Phage: Novel expression vectors that displayed cloned antigens on the virion surface", Science, June 14, 1985, vol. 228, pp. 1315-1317
	Squier et al., "Cell-mediated cytotoxic mechanisms", Current Opinion in Immunology, 1994, vol. 6, pp. 447-452
	Sun et al., "Antitumour activity of a chimeric antibody against the leucocyte antigen CD48", Cancer Immunol. Immunotherapy, 2000, vol. 48, pp. 595-602
	Takebe et al., "Srα Promoter: an efficient and versatile mammalian cDNA Expression System", Molecular and Cellular Biology, Jan. 1988, vol. 8, no. 1, pp. 466-472
	Thompson et al. "A fully human antibody neutralising biologically active human TGFβ2 for use in therapy", J. of Immunol. Methods, 1999, vol. 227, pp. 17-26
	Tomlinson et al., The repertoire of human germline V _H segments with different hypervariable loops", J. Mol. Biol., 1992, vol. 227, pp. 776-798
	The state of the s

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.